A detailed history of British Columbia Investment Management Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, British Columbia Investment Management Corp holds 388,221 shares of BMY stock, worth $20.6 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
388,221
Previous 243,754 59.27%
Holding current value
$20.6 Million
Previous $13.2 Million 21.97%
% of portfolio
0.1%
Previous 0.09%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $5.81 Million - $7.66 Million
144,467 Added 59.27%
388,221 $16.1 Million
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $157,470 - $178,540
3,282 Added 1.36%
243,754 $13.2 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $2.4 Million - $2.86 Million
49,446 Added 25.88%
240,472 $12.3 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $56,732 - $63,435
980 Added 0.52%
191,026 $11.1 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $2,548 - $2,829
-40 Reduced 0.02%
190,046 $12.2 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $39,425 - $44,718
600 Added 0.32%
190,086 $13.2 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $1.47 Million - $1.74 Million
-21,493 Reduced 10.19%
189,486 $13.6 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $5,493 - $3.25 Million
-42,256 Reduced 16.69%
210,979 $15 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $6.53 Million - $7.19 Million
-89,852 Reduced 26.19%
253,235 $19.5 Million
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $2.93 Million - $3.51 Million
-47,581 Reduced 12.18%
343,087 $25.1 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $1.2 Million - $1.4 Million
-22,440 Reduced 5.43%
390,668 $24.4 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $78,400 - $91,835
-1,325 Reduced 0.32%
413,108 $24.4 Million
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $2.68 Million - $2.92 Million
43,240 Added 11.65%
414,433 $27.7 Million
Q1 2021

Apr 30, 2021

SELL
$59.34 - $66.74 $597,969 - $672,538
-10,077 Reduced 2.64%
371,193 $23.4 Million
Q4 2020

Feb 02, 2021

SELL
$57.74 - $65.43 $664,587 - $753,099
-11,510 Reduced 2.93%
381,270 $23.7 Million
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $1.76 Million - $1.96 Million
30,730 Added 8.49%
392,780 $23.7 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $5.8 Million - $6.78 Million
105,718 Added 41.24%
362,050 $21.3 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $13.8 Million - $20 Million
-296,911 Reduced 53.67%
256,332 $14.3 Million
Q4 2019

Feb 12, 2020

SELL
$49.21 - $64.19 $1.31 Million - $1.7 Million
-26,540 Reduced 4.58%
553,243 $35.5 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $3.41 Million - $4.05 Million
-79,814 Reduced 12.1%
579,783 $29.4 Million
Q2 2019

Aug 12, 2019

BUY
$44.62 - $49.34 $616,246 - $681,434
13,811 Added 2.14%
659,597 $29.9 Million
Q1 2019

May 08, 2019

SELL
$45.12 - $53.8 $1.73 Million - $2.07 Million
-38,445 Reduced 5.62%
645,786 $30.8 Million
Q4 2018

Feb 13, 2019

BUY
$48.76 - $63.23 $5.31 Million - $6.88 Million
108,847 Added 18.92%
684,231 $35.6 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $10.5 Million - $11.8 Million
-189,839 Reduced 24.81%
575,384 $35.7 Million
Q2 2018

Aug 09, 2018

SELL
$50.53 - $62.98 $7.22 Million - $9 Million
-142,883 Reduced 15.73%
765,223 $42.3 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $3.67 Million - $4.22 Million
-61,202 Reduced 6.31%
908,106 $57.4 Million
Q4 2017

Feb 20, 2018

BUY
$59.94 - $65.35 $1.23 Million - $1.35 Million
20,598 Added 2.17%
969,308 $59.4 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $52.4 Million - $60.5 Million
948,710
948,710 $60.5 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track British Columbia Investment Management Corp Portfolio

Follow British Columbia Investment Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of British Columbia Investment Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on British Columbia Investment Management Corp with notifications on news.